Skip to content

Trial Summary

The purpose of this study is to assess the performance of imaging agent 64Cu-SARTATE in participants with known or suspected Gastroenteropancreatic (GEP) Neuroendocrine Tumors (NETs) as a potential new way to help diagnose NETs.



ACTRN/NCT /ethics:


Scientific title:

Positron Emission Tomography Imaging of Participants with Known or Suspected Gastroenteropancreatic Neuroendocrine Tumours Using 64Cu-SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II study

Sponsor / Cooperative group:

Clarity Pharmaceuticals Ltd

Trial & Patient Characteristics

Cancer TypeNeuroendocrine
Trial TypeEarly detection, diagnosis, prognosis
PhasePhase II
Age Range18 years and older
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2021-03-02
Anticipated End Date2022-01-08

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting